The analysis on the effect and safety of calcitriol on high turnover osteodystrophy in the treatment of patients with maintenance hemodialysis renal failure / 中国医师进修杂志

ABSTRACT

Objective:To investigate the effect and safety of calcitriol on high turnover osteodystrophy in the treatment of patients with maintenance hemodialysis renal failure.Methods:Eighty patients with maintenance hemodialysis renal failure from April 2018 to June 2020 were selected as study objects and divided into the control group (40 cases) and the observation group (40 cases) by the random number table method. The control group was treated with oral calcium carbonate and other oral calcium preparations. The observation group was additively treated with calcitriol on the basis of the control group for 3 months. The therapeutic efficacy and the incidence of adverse reactions during the treatment were compared between the two groups; the levels of bone metabolism related index, kidney function index, hematocrit (Hct) and hemoglobin (Hb) and other index were compared between the two groups before and after treatment.Results:The total effective rate of the observation group was higher than that of the control group 95.0%(38/40) vs. 80.0%(32/40), the difference was statistically significant ( χ2 = 4.11, P<0.05). After treatment, the levels of immune reactivity parathyroid hormone (iPTH), serum phosphorus, bone alkaline phosphatase (BALP) in the observation group were lower than those in the control group (391.74 ± 28.69) ng/L vs. (468.50 ± 30.52), (1.02 ± 0.16) mmol/L vs. (1.63 ± 0.21) mmol/L, (70.59 ± 4.15) U/L vs.(73.64 ± 4.09) U/L, and the level of serum calcium was higher than that in the control group [(2.05 ± 0.13) mmol/L vs. (1.93 ± 0.11) mmol/L, the differences were statistically significant ( P<0.05). After the treatment, the levels of serum creatinine (SCr), blood urea nitrogen (BUN), serum albumin (ALB) and the incidence of adverse reactions between the two groups had no significant differences ( P>0.05). Conclusions:The administration of calcitriol in the treatment of patients with maintenance hemodialysis renal failure can improve the status of high turnover osteodystrophy and anemia, and has a high safety.